Mandate

Vinge advises Smart Eye AB in conjunction with its listing on Nasdaq First North

November 11, 2016

Vinge has advised Smart Eye AB in connection with the listing of Smart Eye’s shares on Nasdaq First North.

In connection with the listing, a new issue of not more than 1 750 000 shares was performed whereupon Smart Eye will receive not more than SEK 80 500 000. The offer is directed to the general public and institutional investors. The prospectus was published on 10 November and the first day of trading is 7 December.

Vinge’s team primarily consisted of responsible partner Anders Strid, Magnus Pauli (client relationship), Frida Bäckegren (project manager due diligence and prospectus), Joel Zetterström and Natalie Bäck (IP), Jonas Lindeblad (employment), Björn Nicolai and Karin Wisenius (EU and competition), Victor Ericsson (tax) and company assistant Camilla Andersson.

Related

Vinge advises Meribel Pharma Solutions

Vinge advises Meribel Pharma Solutions in connection with the sale of their production facility in Uppsala to Ofichem. The Uppsala site specializes in small-scale, early-phase development work.
August 13, 2025

Vinge advises Isofol Medical AB (publ) in connection with its rights issue of units

Through the rights issue of units, consisting of shares and warrants, and the exercised over-allotment issue, Isofol will receive approximately SEK 84 million and may receive an additional maximum of approximately SEK 110 million upon exercise of all warrants at the highest subscription price.
August 01, 2025

Vinge advises Oncorena in connection with share issue

Vinge advises Oncorena Holding AB in connection with a share issue of approximately SEK 133 million.
July 30, 2025